For patients with chronic liver disease, statin use is associated with reduced risk for hepatocellular carcinoma and hepatic decompensation.

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

Hepatitis C virus (HCV) infection remains a major global health burden, affecting millions worldwide and contributing significantly to hepatocellular carcinoma (HCC) development.

In this video, Michael Cecchini, MD, discusses “practice-changing” data from the CheckMate 8HW study, which were presented at ASCO Gastrointestinal Cancers Symposium.

PRINCETON, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- Teclison, Inc., a clinical-stage oncology company dedicated to advancing immunotherapeutic treatments for solid tumors, today announced that Ray Lee ...

An expert discusses how, for advanced unresectable hepatocellular carcinoma (uHCC), clinicians monitor treatment efficacy ...

The field of cardio-oncology has expanded over the past 2 decades to address the ever-increasing issues related to cardiovascular disease in patients with cancer and survivors. There is increasing ...

Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...

HONG KONG, China I March 16, 2025 I Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been ...

A research team led by Prof. SUN Cheng from the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences, along with ...

A research team led by Prof. SUN Cheng from the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences, along with collaborators from the Agency for Science, ...

Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events included hypertension and anemia. Evidence ...